Physician profile
Steven Smith
NPI 1114360013
$3,570.60
in general payments reported to CMS, 2019-2025
27 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $624 · 2021: $704 · 2022: $611 · 2023: $425 · 2024: $324 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $607.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $538.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $349.34 | 2021-2024 | Ubrelvy, Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $264.02 | 2019-2024 | |
| Allergan, INC. | $231.42 | 2019-2020 | |
| Pfizer INC. | $216.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $191.97 | 2019-2025 | Pediarix, Rotarix, Bexsero |
| Novo Nordisk INC | $177.07 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $148.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.77 | 2020-2022 | |
| Cardiva Medical, INC. | $98.26 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Preventric Diagnostics, INC. | $78.88 | 2021 | |
| Argon Medical Devices, INC. | $67.29 | 2019 | |
| Exact Sciences Corporation | $65.36 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $62.10 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.25 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $59.41 | 2022-2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $35.95 | 2021 | |
| Amgen INC. | $31.28 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.28 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.53 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.27 | 2021 | |
| Nevro Corp. | $21.37 | 2022 | |
| Edwards Lifesciences Corporation | $18.15 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2023 | Rexulti |
| Medline Industries Lp | $15.86 | 2023 | |
| Hikma Pharmaceuticals USA | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.